Eric Mark Green - Aug 6, 2024 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Signature
/s/ Louis Lalli
Stock symbol
WST
Transactions as of
Aug 6, 2024
Transactions value $
-$7,173,713
Form type
4
Date filed
8/8/2024, 04:16 PM
Previous filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Options Exercise $1.83M +30.7K +18.98% $59.64 193K Aug 6, 2024 Direct F1
transaction WST Common Stock Sale -$9.36M -30.7K -15.95% $304.71 162K Aug 6, 2024 Direct F1, F2
transaction WST Common Stock Options Exercise $358K +6K +3.71% $59.64 168K Aug 6, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Stock Option (Right to Buy) Options Exercise $0 -30.7K -83.67% $0.00 6K Aug 6, 2024 Common Stock 30.7K $59.64 Direct F3
transaction WST Stock Option (Right to Buy) Options Exercise $0 -6K -100% $0.00* 0 Aug 6, 2024 Common Stock 6K $59.64 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.
F2 The price reported in Column 4 is a weighted average price.
F3 This option is fully vested.